Merck Serono gets green light to resume Stimuvax therapeutic cancer vaccine programme in lung cancer
This article was originally published in Scrip
Executive Summary
Merck Serono, a division of Merck KGaA, is resuming two Phase III trials, START and INSPIRE, in non-small cell lung cancer (NSCLC), for its therapeutic cancer vaccine Stimuvax (BLP25 liposome vaccine) that it was forced to temporarily suspend in March after a single patient in another trial developed encephalitis, or acute brain inflammation.